ArticleMikrochimica acta2025
A synchronous fluorescence biosensor mediated by hydrogen-bonding interaction for highly selective detection of dopamine.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A highly selective and sensitive silicon nanoparticles (Si NPs) biosensor was developed for dopamine (DA) detection utilizing synchronous fluorescence spectroscopy (SFS). Si NPs were synthesized via a one-step hydrothermal method, utilizing 3-aminopropyltriethoxysilane (APTES) as the silane precursor and polyethyleneimine (PEI) as the reducing agent. The Si NPs exhibited a spherical morphology, with an average diameter of 3.7 nm. Additionally, the Si NPs demonstrated remarkable fluorescent properties. When integrated into the DA detection process utilizing SFS, the synchronous fluorescence spectrum of the DA system exclusively exhibits a peak at 530 nm, whereas systems involving epinephrine and norepinephrine both display peaks at 484 nm and 530 nm. Consequently, this detection system exhibits a high capacity for effectively differentiating between DA and other catecholamines (epinephrine and norepinephrine), ensuring a high degree of specificity in the detection process. Additionally, this combined approach also presents a strong linear relationship between the enhancement of synchronous fluorescence intensity (F
Indexed as
Identifiers
39954106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.